scholarly journals Stem Cell Therapy for Human Liver Cirrhosis: A Cautious Analysis of the Results

Stem Cells ◽  
2007 ◽  
Vol 25 (9) ◽  
pp. 2383-2384 ◽  
Author(s):  
Stefania Lorenzini ◽  
Pietro Andreone
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Human Liver ◽  
Human Liver Cirrhosis

Steroids reduce the efficacy of mesenchymal stem cell therapy for liver cirrhosis

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S48-S50 ◽  
Author(s):  
Xiaodong Chen ◽  
Yurun Gan ◽  
Ying Wang ◽  
Yufang Shi
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mesenchymal Stem Cell Therapy

scholarly journals Mesenchymal stem cell therapy for advanced liver cirrhosis: A case report

JGH Open ◽  
2017 ◽  
Vol 1 (4) ◽  
pp. 153-155 ◽  
Author(s):  
Ruveena Rajaram ◽  
Baskar Subramani ◽  
Basri J J Abdullah ◽  
Sanjiv Mahadeva
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Case Report ◽  
Mesenchymal Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Mesenchymal Stem Cell Therapy ◽  
Advanced Liver Cirrhosis

scholarly journals Stem Cell Therapy in Liver Cirrhosis

2016 ◽  
pp. 153-157
Author(s):  
Ghassemi A ◽  
◽  
Ommati H ◽  
Esmaeilzadeh A ◽  
Kooshyar MM ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy

scholarly journals Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV- related liver failure and liver cirrhosis

2020 ◽  
Author(s):  
Yifan Jia ◽  
Xin Shu ◽  
Xiaoan Yang ◽  
Haixia sun ◽  
Huijuan Cao ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Liver Failure ◽  
Stem Cell Therapy ◽  
Prolonged Treatment ◽  
Therapeutic Effects ◽  
Failure Group

Abstract Background: This study aimed to investigate the therapeutic effect of umbilical cord mesenchymal stem cells (UCMSCs) on HBV-related liver failure and liver cirrhosis and to compare the different efficacies of UCMSCs after different treatment courses.Methods: This was an observational study that retrospectively considered a three-year period during which 513 patients who received stem cell infusion met the criteria of hepatic failure and liver cirrhosis were identified from databases of the Third Affiliated Hospital of Sun Yat-sen University. Eligible patients were categorized into the liver failure group and liver cirrhosis group. The two groups were divided into different subgroups according to the times of stem cell therapy. In the liver failure group, group A received more than 4 weeks and group B received less than 4 weeks. In the liver cirrhosis group, patients who received more than 4 weeks of stem cell therapy belonged to group C, and group D received less than 4 weeks. The patients were followed up for 24 weeks. The demographics, clinical characteristics, biochemical factors, and MELD scores were recorded and compared among different groups.Results: A total of 64 patients met the criteria of liver failure, and 59 patients met the criteria of liver cirrhosis. After UCMSC treatments, the levels of ALT, AST, and TBIL at all postbaseline time points were significantly lower than those at baseline in the liver failure group and liver cirrhosis group; the PTA and MELD scores only gradually improved in the liver failure group. Four weeks after UCMSC treatment, patients with prolonged treatment with UCMSCs had higher TBIL decline levels than patients who terminated treatment with UCMSCs. After more than 4 weeks of UCMSC treatment, there was no statistically significant difference in the levels of change for ALT, AST, TBIL, PTA value and the MELD score between patients with liver failure with prolonged treatment with UCMSCs and patients with liver cirrhosis with prolonged treatment with UCMSCs at all observation weeks. However, the median decline and cumulative decline in the TBIL level of patients with liver failure with a standard 4-week treatment course were higher than those of patients with liver cirrhosis with a standard 4-week treatment course.Conclusion: Peripheral infusion of UCMSCs showed good therapeutic effects for HBV-related liver failure and liver cirrhosis. Prolonging the treatment course can increase the curative effect of UCMSCs for end-stage liver disease, especially for patients with cirrhosis.

scholarly journals Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

2017 ◽  
Vol 4 (2) ◽  
Author(s):  
Gounder Sellamuthu Subbanna ◽  
Kodiappan Radha ◽  
Chan Soon Choy ◽  
Veerakumarasivam Abhi ◽  
Subramani Baskar
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Adult Stem Cell ◽  
Future Perspectives ◽  
Current Practices

scholarly journals A Proposed Novel Stem Cell Therapy Protocol for Liver Cirrhosis

2015 ◽  
Vol 24 (3) ◽  
pp. 533-540 ◽  
Author(s):  
Po-Cheng Lin ◽  
Tzyy-Wen Chiou ◽  
Zung-Sheng Lin ◽  
Ko-Chang Huang ◽  
Yi-Chun Lin ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Therapy Protocol

scholarly journals Enhanced therapeutic effects of umbilical cord mesenchymal stem cells after prolonged treatment for HBV-related liver failure and liver cirrhosis

2020 ◽  
Author(s):  
Yifan Jia ◽  
Xin Shu ◽  
Xiaoan Yang ◽  
Haixia sun ◽  
Huijuan Cao ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Liver Cirrhosis ◽  
Stem Cell ◽  
Cell Therapy ◽  
Liver Failure ◽  
Stem Cell Therapy ◽  
Prolonged Treatment ◽  
Therapeutic Effects ◽  
Failure Group

Abstract Background: This study aimed to investigate the therapeutic effect of umbilical cord mesenchymal stem cells (UCMSCs) on HBV-related liver failure and liver cirrhosis and to compare the different efficacies of UCMSCs after different treatment courses. Methods: This was an observational study that retrospectively considered a three-year period during which 513 patients who received stem cell infusion met the criteria of hepatic failure and liver cirrhosis were identified from databases of the Third Affiliated Hospital of Sun Yat-sen University. Eligible patients were categorized into the liver failure group and liver cirrhosis group. The two groups were divided into different subgroups according to the times of stem cell therapy. In the liver failure group, group A received more than 4 weeks and group B received less than 4 weeks. In the liver cirrhosis group, patients who received more than 4 weeks of stem cell therapy belonged to group C, and group D received less than 4 weeks. The patients were followed up for 24 weeks. The demographics, clinical characteristics, biochemical factors, and MELD scores were recorded and compared among different groups. Results: A total of 64 patients met the criteria of liver failure, and 59 patients met the criteria of liver cirrhosis. After UCMSC treatments, the levels of ALT, AST, and TBIL at all postbaseline time points were significantly lower than those at baseline in the liver failure group and liver cirrhosis group; the PTA and MELD scores only gradually improved in the liver failure group. Four weeks after UCMSC treatment, patients with prolonged treatment with UCMSCs had higher TBIL decline levels than patients who terminated treatment with UCMSCs. After more than 4 weeks of UCMSC treatment, there was no statistically significant difference in the levels of change for ALT, AST, TBIL, PTA value and the MELD score between patients with liver failure with prolonged treatment with UCMSCs and patients with liver cirrhosis with prolonged treatment with UCMSCs at all observation weeks. However, the median decline and cumulative decline in the TBIL level of patients with liver failure with a standard 4-week treatment course were higher than those of patients with liver cirrhosis with a standard 4-week treatment course. Conclusion: Peripheral infusion of UCMSCs showed good therapeutic effects for HBV-related liver failure and liver cirrhosis. Prolonging the treatment course can increase the curative effect of UCMSCs for end-stage liver disease, especially for patients with cirrhosis.

Sign in / Sign up

Export Citation Format

Share Document